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Abstract
Transcriptional repressor CTCF is an important regulator of chromatin 3D structure, facili-
tating the formation of topologically associating domains (TADs). However, its direct effects
on gene regulation is less well understood. Here, we utilize previously published ChIP-seq
and RNA-seq data to investigate the effects of CTCF on alternative splicing of genes with
CTCF sites. We compared the amount of RNA-seq signals in exons upstream and down-
stream of binding sites following auxin-induced degradation of CTCF in mouse embryonic
stem cells. We found that changes in gene expression following CTCF depletion were sig-
nificant, with a general increase in the presence of upstream exons. We infer that a possible
mechanism by which CTCF binding contributes to alternative splicing is by causing pauses
in the transcription mechanism during which splicing elements are able to concurrently act
on upstream exons already transcribed into RNA.
Keywords: Alternative splicing, CTCF, CCCTC-binding factor, chromatin structure,
chromatin topology, gene regulation
1. INTRODUCTION
Recent Hi-C imaging and sequencing technology have elucidated the importance of 3-D
chromatin structure and epigenetics in gene regulation [1, 2, 3]. In addition to containing
compartments of active, gene rich euchromatin and compartments of inactive, gene poor
heterochromatin, chromatin is spatially partitioned into topologically associating domains
(TADs) [4]. TADs are insulated regions of chromatin, where sequences within each respective
region have more frequent interactions than with sequences in other regions of the genome.
Borders of TADs are often marked by the presence of CCCTC-binding factor (CTCF) [5].
CTCF is a highly conserved zinc finger protein that recognizes 50 base pair variant sequences
throughout the genome [6]. CTCF is thought to facilitate TAD formation by binding to two
distant locations of DNA and then binding to itself, creating a loop of chromatin [7, 2].
Recent studies of CTCF have shown it is essential to loop formation, driving epigenetic
forces of gene expression, but it is not essential to compartmentalization of chromatin into
active and inactive regions [8].
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Although CTCFs role in loop formation is well characterized, its role in gene regulation
is less well understood. Previous studies have noted CTCFs importance in gene regulation
during development, showing that disruption of CTCF affects gene transcription in mouse
oocytes [9]. Other studies have shown that disruption of CTCF affects essential genetic
pathways of cell proliferation, differentiation, and apoptosis [10]. Recent studies have linked
CTCF to alternative splicing of nearby genes. In mammalian CD45 genes, CTCF is thought
to promote inclusion of exon 5 by pausing RNA polymerase II [11]. Genome-wide, CTCF
is thought to facilitate exon inclusion, or alternate exon usage, during RNA splicing by
bringing exons in closer proximity to their promoters [12]. However, these studies remain
limited in the scope of genes investigated or largely correlative, demanding a functional
investigation of the effect of CTCF on alternative splicing.
Here, we used previously published ChIP-seq and mRNA-seq data from a CTCF knock-
down mouse embryonic stem cell (mESC) model to examine the extent of CTCF dependent
alternative splicing events [8]. Specifically, we compared exon usage in genes that contain a
CTCF binding site in mESC lines tagged with an auxin-inducible degron (AID) for CTCF
and untagged wild type, before and after treatment with auxin. We provide evidence that
the presence of intragenic CTCF alters exon usage in a transcription direction dependent
manner. We show that degradation of CTCF in an AID system results in a higher propor-
tion of upstream exon usage in alternative splicing. These results support the direct role
of CTCF in regulating alternative splicing during embryogenesis, and nominate a heritable
epigenetic system that can be probed to better understand the pathology of alternative
splicing driven diseases that arise during development.
2. METHOD
2.1. Data Retrieval
All data analyzed in this study were from the previously published Nora et al., 2017
paper [8]. Expression levels for mRNA fragments were retrieved from the National Center
for Biotechnology Gene Expression Omnibus (GSE98671). Experimental parameters and
total reads were obtained from the supplements of Nora et al., 2017. CTCF ChIP-seq peak
locations and magnitudes were provided by the Mirny Lab located at the Massachusetts
Institute of Technology (mirnylab.mit.edu). Mouse genome mappings (NCBI37/mm9) were
available from the University of California Santa Cruz (UCSC) Genome Browser.
2.2. Identification and Ranking of Gene Bound CTCF Sites
All calculations were done on R (Version 3.4.1) using tools from the Bioconductor project.
First, the most prominent CTCF sites that were successfully degraded by auxin were isolated.
From the 43,607 CTCF ChIP peaks in the untreated sample, 13,131 peaks remained or were
not fully degraded in the treated sample. These 13,131 peaks were identified by genomic
location using the findOverlaps function and subsequently removed from analysis. The
30,554 remaining peaks were then cross referenced with the known gene locations of the
mm9 assembly to find CTCF sites that were located within protein coding sequences. This
final pool of 16,665 peaks were ranked by peak magnitude and the highest five thousand
were examined in this study.
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2.3. Quantifying mRNA-Seq Reads
For each of the 5,000 CTCF sites selected, the gene containing the CTCF site was found
and the isoform with the most comprehensive selection of exons was selected. The locations
of all exons upstream and downstream of the site were then identified. For each RNA-seq
tag Density file, the signals in the exons upstream were summed. The resulting sum was
divided by the total signal for the entire RNA-seq file and multiplied by the total number
of reads in the experiment to estimate the number of reads in the upstream exons:
RmRNA =
∑
exon Signal∑
total Signal
Rtotal,
where RmRNA is the mRNA-seq Reads and Rtotal the total number of reads in our experiment.
The same calculation was done for the downstream exons. Estimated reads were rounded
to the nearest whole number and pooled with data from experimental replicates under the
same conditions.
2.4. Statistical Analysis
The statistic used to compare distribution of isoforms around CTCF sites is the propor-
tion (P ) of reads upstream (U) compared to reads downstream (D), P = U
D
. This statistic
will hereafter be referred to as the proportion of a CTCF site. The final set of sites with
valid proportion values consisted of 2,636 sites.
3. RESULTS
3.1. Orientation and Shift in Proportions
Before the influence of CTCF on alternative splicing can be examined, directionality ef-
fects due to CTCF and transcriptional direction have to be accounted for. Effects of various
experimental conditions were quantified by dividing the proportion after treatment by the
proportion before treatment. Kernel Density plots for the log change in proportions are plot-
ted in Figure 1. As Figure 1a shows, changes in log expression ratio around the CTCF site
does not depend on CTCF orientation. On the other hand, Figure 1b shows that changes in
log expression ratios are symmetric with respect to transcriptional direction. A two-sample
t-test shows significant difference (p.value = 2E − 63) between the distributions. Thus,
comparisons must be made with respect to transcription orientation, with upstream of a
CTCF site being defined as transcriptionally upstream and downstream as transcriptionally
downstream. Once corrected for transcriptional direction, change in log expression ratio is
positive (Figure 1c).
3.2. Contingency Tables and Tests for Significance
To get an understanding of specific changes in isoform distribution and evaluate the sig-
nificance of the change at specific CTCF sites, contingency tables were built for each site.
Observations consist of the number of fragments detected upstream and downstream of the
CTCF site with Fishers exact test conducted to evaluate the difference. Fishers exact test
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(a) (b) (c)
Figure 1: Log change in proportions in CTCF-AID tagged cells from untreated to auxin 2 days (N = 2636).
(a) Distributions grouped by CTCF orientation overlap and show no significant difference. (b) Distributions
grouped by transcription orientation are mirrored and show significant difference (p.value = 7E63). (c)
When proportions are recalculated to account for transcriptional orientation, log change in proportions
show significant deviation from zero (p.value = 2E63).
was preferred over chi-squared test because reads of mRNA fragment tend to be skewed and
vary wildly between very large and very small counts. Multiple testing correction was per-
formed using Bonferroni correction, resulting in a more conservative alpha for significance
testing, α = 0.05/2636 = 1.9E−5. Given the noisiness of the data, the reduced power owing
to increased conservativeness of the test and FDR control were acceptable. Three contin-
gency tables were constructed for each site to evaluate the influence of CTCF degradation
on alternative splicing. The parameters for the tests are expressed in Table 1.
Test Sample Comparison Observed
1 CTCF-AID tagged cells Untreated vs auxin 2 days
Distribution of fragments
upstream and downstream
of the CTCF site
2 Wildtype untagged cells Untreated vs auxin 2 days
Distribution of fragments
upstream and downstream
of the CTCF site
3 Untreated tagged and untagged cells CTCF-AID tagged vs wildtype untagged
Distribution of fragments
upstream and downstream
of the CTCF site
Table 1: Description of tests conducted on contingency tables
3.3. Changes in Proportions in CTCF Bound Genes
The distribution of p-values show anti-conservative trends for all three tests (Figure 2),
suggesting that the alternative hypothesis of equal exon usage in genes with CTCF binding
sites may be true for some genes. In CTCF-AID tagged cells, treatment with auxin resulted
in significant changes in proportions at 464 CTCF sites (Figure 2a). Surprisingly, 356 sites
in wildtype untagged cells also showed significant change after auxin treatment (Figure 1b)
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(a) (b) (c)
(d) (e) (f)
Figure 2: Factors that Affect Alternative Splicing. (a c) Distribution of p-values from Fishers exact test
of factors influencing splicing. (a) Test 1 evaluates the effect of auxin on CTCF-AID tagged cells. (b) Test
2 evaluates the effect of auxin on wildtype untagged cells. (c) Test 3 evaluates the effect of CTCF-AID
tagging. (d f) scatter plots mapping proportions in control and experiment and color coded by significance
of p-values. (d, e) Untreated vs auxin 2 days on tagged and untagged WT cells. (f) Untagged WT vs
CTCF-AID tagged untreated cells.
even though treatment wouldnt result in CTCF depletion. Moreover, comparing untreated
CTCF-AID to untreated untagged cells shows 483 significant sites (Figure 2c).
A large magnitude of change in proportion isnt always significant while a large number
of site that showed moderate proportion changes were significant. Significant sites showed
both positive and negative change in proportions (Figure 3a). Nonsignificant points showing
large changes had relatively small numbers of reads, making it possible for small variations
to show a large magnitude change but still give high p-values; meanwhile, sites showing
significance close to the center have a large number of reads (Supplementary Table Sites).
A number of sites overlap in the tests for which they are significant (Figure 3b). There
are more overlaps than expected for such stringent selection, suggesting that there may be
common mechanisms causing these sites to display greater variation.
3.4. Distribution of Proportion Change
Assuming that all CTCF sites are in one population and impacted similarly, the distri-
bution of proportion changes can be viewed as a whole to analyze how treatment affected
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(a) (b)
Figure 3: CTCF sites grouped by tests they are significant for. (a) Scatter plot mapping log change in
proportion in wildtype untagged cells to log change in CTCF-AID tagged cells. (b) Venn diagram showing
overlaps in test significance. There were 1718 sites which were not significant for any of the tests.
splicing. Exposure to auxin for 2 days caused proportions to significantly increase in CTCF-
AID tagged cells and to significantly decrease in wild-type untagged cells (Figure 4a). As
expected, treated tagged cells showed significant increase in proportions compared to treated
untagged cells. Surprisingly, untreated tagged cells also showed significant increases over un-
treated untagged cells. However, it is of note that these changes were smaller in magnitude
(Figure 4b).
4. DISCUSSION
While CTCF has been noted as a key player in shaping the 3D structure of chromatin,
its direct effects on gene regulation, and in particular alternative splicing, is less well char-
acterized. As noted, this study investigated the direct effects of CTCF on alternative exon
usage in mouse embryonic stem cells. Using previously published ChIP-seq and RNA-seq
data from Nora et al., 2017, we investigated alternative splicing in genes containing a CTCF
binding site. We quantified and compared the changes in alternative exon usage after the
CTCF was removed from a CTCF bound gene was degraded.
We found that degrading CTCF using auxin in CTCF-AID tagged cells resulted in an
increase in the proportion of upstream fragments used in final mRNA transcripts. This
finding supports Shukla et al, 2011s hypothesis that CTCF binding to DNA blocks tran-
scription proteins and causes pauses in mRNA transcription. Splicing occurs concurrently
with transcription, and thus when transcription is paused due to CTCF, splicing elements
are able to act upon RNA upstream that were already transcribed with greater frequency.
Depletion of CTCF likely prevents these pauses in transcription, giving splicing elements
less opportunity to act on exons upstream of CTCF sites. Here, we provide evidence for
this mechanism by showing that CTCF depletion results in greater upstream exon usage in
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(a)
(b)
Figure 4: Log Change in proportions across treatments. (a) Comparing untreated to auxin 2 days. Untagged
cells show decrease with p.value = 3E − 16. Tagged cells show increase with p.value = 2E − 63. (b)
Comparing wildtype untagged to CTCF-AID tagged. Untreated cells show increase with p.value = 2E−51.
Treated cells show increase with p.value = 5E − 171.
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mRNA formation.
Although these findings seem promising, it should be noted that significant differences in
the proportions of exon usage were also observed in control cases that should exhibit none.
In particular, there were 384 genes that exhibited a significant change in alternative splicing
in the wild type, untagged cells after treatment with auxin. When comparing wild type,
untagged cells with CTCF-AID tagged cells without the presence of auxin, we found 483
CTCF bound genes that exhibited significantly different alternative splicing among these
two conditions. Although the magnitudes of the changes were smaller than those between
the experimental condition and control, these changes are alarming as they suggest that the
AID tagging method itself may cause changes in gene expression. One explanation is that
the tagging process affected the expression levels of genes related to splicing factors and
transcription controls. Another is that although ChIP-seq shows tagged CTCF still bound
to DNA, the binding efficiency may be impacted to an extent that differences in splicing
may be observed. What may be even harder to explain is why untagged cells showed lower
proportions after exposure to auxin. Untagged cells did not have their CTCF degraded,
showed no difference in gene expression levels, and did not suffer from the same cytotoxic
effects that tagged cells displayed. Nonetheless, untagged cells showed an anti-conservative
distribution of p-values and a significantly negative change in proportion. These observations
should be examined further, or they may undermine the conclusions made above.
The effect of CTCF binding on alternative splicing in mouse embryonic stem cells is
apparent in this study. We showed a number of genes that exhibit a change in upstream
exon usage after depletion of CTCF, suggesting a functional role of CTCF in determining
alternatively spliced mRNA transcripts. As noted by Li et al., 2016, alternative splicing
and the resulting isoforms have great impact not only on biodiversity and genetic variation
but also on disease [13]. Understanding the mechanisms behind alternative splicing can
provide insight into the pathology of diseases such as developmental disorders and cancers.
This has already been hinted by Filipova et al., 1998 when the authors associated CTCF
binding with deletions resulting in breast and prostate cancers [14]. Perhaps more exciting,
understanding the decision-making machinery behind alternative splicing can expose po-
tential vulnerabilities in alternative splicing driven mechanism and inform potential targets
for therapy. Future work should focus on characterizing the types of genes and pathways
affected by CTCF mediating alternative splicing.
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